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PATTERNS OF THERAPY, HEALTH CARE UTILIZATION, AND HEALTH 
CARE COSTS IN PATIENTS WITH PULMONARY ARTERIAL 
HYPERTENSION (PAH) INITIATING THERAPY WITH SILDENAFIL: 
FINDINGS FROM RETROSPECTIVE ANALYSES OF ADMINISTRATIVE 
HEALTH CARE CLAIMS DATA
Mychaskiw MA1, Berger A2, Mardekian J1, Oster G2
1Pﬁ zer Inc, New York, NY, USA; 2Policy Analysis Inc., Brookline, MA, USA
OBJECTIVES: To examine patterns of therapy, health care utilization, and health care 
costs among PAH patients initiating therapy with sildenaﬁ l in a real-world setting. 
METHODS: Patients aged ≥18 years with evidence of PAH (ICD-9-CM diagnosis 
codes 416.0, 416.8) and ≥1 claims for sildenaﬁ l between June 1, 2005, and September 
30, 2008 were identiﬁ ed from a large administrative health care claims database. 
Patients with <6 months of pretreatment data were excluded. Patients were followed 
from index date (ﬁ rst-noted sildenaﬁ l claim) until health plan disenrollment or end of 
study (follow-up). Patterns of therapy with sildenaﬁ l were examined, including 
numbers of prescriptions and associated therapy-days and compliance; the latter was 
measured using medication possession ratio (MPR, ratio of total therapy-days to total 
days of follow-up). For the subgroup of patients with ≥6 months of follow-up data, 
health care utilization and costs were compared between the 6-month period preceding 
and following the index date. RESULTS: Of 855 PAH patients identiﬁ ed who began 
therapy with sildenaﬁ l and met study inclusion criteria (mean age, 53 years; 69% 
women), 32% had comorbid lung conditions and 17% connective tissue disorders. 
Over a mean duration of follow-up of 423 days (median, 357 days), patients averaged 
6 prescriptions for sildenaﬁ l spanning 209 therapy-days (mean MPR = 0.78). Health 
care utilization was largely unchanged between the 6-month preindex and postindex 
periods. Mean costs of outpatient care decreased by $501 ($8321 vs. $7820 during 
preindex); mean total health care costs increased by $4137 (95% CI, $38,815–
$42,952), primarily due to increased costs of PAH-related pharmacotherapy (includ-
ing sildenaﬁ l) (P < 0.01 for all comparisons). CONCLUSIONS: PAH patients initiating 
sildenaﬁ l therapy are relatively compliant with treatment. Although health care utiliza-
tion is largely unchanged following initiation of sildenaﬁ l therapy, total health care 
costs increase, primarily due to costs of PAH-related pharmacotherapy. Further 
research is needed to better understand the real-world impact of sildenaﬁ l on patient 
health outcomes.
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HEALTH CARE UTILIZATION AFTER PLATELET AGGREGATION 
INHIBITORS
Löfroth E, Murén KJ, Bruce S
IMS Health, Stockholm, Sweden
OBJECTIVES: To analyze the annual health care utilization by patients dispensed 
platelet aggregation inhibitors excluding heparin. METHODS: This was a retrospec-
tive longitudinal descriptive database study of the utilization of health care of patients 
from the South-West region of Sweden (1.5 million inhabitants). All patients who were 
dispensed platelet aggregation inhibitors, excluding heparin (N05AC) during 2007 
and who had a cardiovascular principal diagnosis (chapter 9, ICD-10) were included 
in the study. Only costs related to cardiovascular care (i.e. visits with a cardiovascular 
diagnosis) were included. RESULTS: a total of 46,742 patients had at least one dis-
pensed platelet aggregation inhibitor and at least one cardiovascular related health 
care visit during 2007 in the South-West region of Sweden. a total of 15,779 had at 
least one in-patient stay, 18,211 had at least one out-patient visit, and 28,432 had at 
least one primary care visit. The total costs of in- and out-patient care, primary care, 
and of platelet aggregation inhibitors, excluding heparin was 1.5 billion SEK. The 
greatest cost contributor was in-patient care, a total of 1.2 billion SEK, 74,501 SEK 
per patient in in-patient care. The total cost for out-patient care was 98 million SEK, 
5371 SEK per patient. The total cost for primary care was 92 million SEK, 3223 SEK 
per patient. The total drug cost was 43 million SEK, 912 SEK per patient. CONCLU-
SIONS: For those patients who had at least one health care visit and who were dis-
pensed platelet aggregation inhibitors the drug cost amounted to less than 3% of the 
total annual cost. In-patient care represented as much as 80% of the total annual 
costs.
PCV56
RENAL MORBIDITY, MORTALITY, AND COSTS IN INDIVIDUALS 
UNDERGOING INVASIVE CARDIAC CATHETERIZATION PROCEDURES 
WITH LOW-OSMOLAR CONTRAST MEDIA: A LARGE RETROSPECTIVE 
DATABASE ANALYSIS
Min J1, Ryan A2, Spalding J3
1Weill Cornell Medical College, New York, NY, USA; 2GE Healthcare Clinical Data Services, 
Princeton, NJ, USA; 3GE Healthcare, Barrington, IL, USA
OBJECTIVES: To investigate in-hospital hemodialysis (HD), length of stay (LOS), 
mortality, and costs following use of low-osmolar contrast media (LOCM) in patients 
undergoing invasive cardiac catheterization procedures. METHODS: This retrospec-
tive analysis used the Premier PerspectiveTM database, which contains patient-level 
data. In-patient adults without prior HD who underwent invasive cardiac catheteriza-
tion procedures with LOCM during 2007–2008 were studied (iohexol: n = 36,118, 
iopamidol: n = 36,089, ioversol: n = 135,619). Propensity score weighted and multi-
variate logistic regression analyses were used. RESULTS: In-hospital HD rates were 
low after exposure to any of the 3 LOCM (0.9% iohexol, 1.0% iopamidol, 1.0% 
ioversol). Risk of HD did not differ between iopamidol and iohexol, but ioversol 
demonstrated increased risk of HD compared to iohexol (adjusted Odds Ratio [OR] 
1.17, 95% CI 1.02–1.35) and iopamidol (adjusted OR 1.17, 95% CI 1.02–1.34). For 
in-hospital mortality (2.1% iohexol, 2.3% iopamidol, 1.9% ioversol), no between-
group differences were statistically signiﬁ cant. Similarly, all-cause 30-day readmission 
rates (10.8% iohexol, 10.4% iopamidol, 10.6% ioversol) did not differ signiﬁ cantly 
between the groups. Contrast-induced acute kidney injury-related 30-day readmission 
rates were 0.2% in all 3 groups. There was no signiﬁ cant difference in the mean 
adjusted LOS between the groups (6.2–6.3 days). Iohexol was associated with a sig-
niﬁ cantly lower (P < 0.001) mean adjusted initial hospitalization cost ($21,591) 
compared with either iopamidol ($23,482) or ioversol ($23,484) and with a signiﬁ -
cantly lower (P < 0.001) mean adjusted initial hospitalization cost post-procedure 
($10,512) compared with either iopamidol ($11,393) or ioversol ($11,187). CON-
CLUSIONS: In this large cohort of hospitalized patients, in-hospital HD rates were 
low after invasive cardiac catheterization procedures with LOCM. The risk of HD 
was comparable with iohexol and iopamidol, while ioversol was associated with a 
signiﬁ cantly higher risk. While in-hospital mortality rates, LOS, and all-cause 30-day 
readmission rates did not differ signiﬁ cantly between the 3 LOCM, iohexol was 
associated with signiﬁ cantly lower cost.
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COST ANALYSIS OF THE MEDICINE TREATMENT OF SOUTH AFRICAN 
PATIENTS WITH METABOLIC SYNDROME
Burger JR, Serfontein JHP, Lubbe MS
North-West University, Potchefstroom, South Africa
OBJECTIVES: In the absence of data on the economic impact of the metabolic syn-
drome amongst South Africans, this study aims to investigate the direct cost of treat-
ment associated with the syndrome using data from a South African Pharmacy Beneﬁ t 
Management company (PBM). METHODS: A non-experimental, retrospective quan-
titative drug utilization review was performed using prescription claims data. Data for 
a 4-year period (January 1, 2005 to December 31, 2008) were analyzed. The direct 
costs of medicine treatment were computed by the addition of the medical scheme 
contribution and the patient levy. All costs were respectively expressed in 2005, 2006, 
2007 and 2008 $U.S. RESULTS: Prescription claims data for a total of 10,567 patients 
in 2005; 12,123 in 2006; 12,769 in 2007 and 13,201 in 2008 with a diagnosis of 
metabolic syndrome were included in the study. The total direct cost of medicine 
treatment for these patients accounted for $7,921,831.10 in 2005, compared to 
$9,290,773.29 in 2006, $9,780,931.85 in 2007 and $8,515,349.53 in 2008. These 
costs represented 2.76% (N = $287,538,709.70) of all claims during 2005, compared 
to 3.18% (N = $292,314,629.60) of claims in 2006, 3.58% (N = $273,086,935.30) 
in 2007, and 3.87% (N = $220,144,319.80) in 2008. Private insurers contributed 
90.91% (N = $7,921,831.10) towards the treatment of patients with metabolic syn-
drome in 2005, compared to 89.92% (N = $9,290,773.29) during 2006, 89.50% (N 
= $9,780,931.85) in 2007 and 87.17% (N = $8,515,349.53) in 2008. Patients paid 
on average $68.15 ± 106.18 (median $17.59) out-of-pocket for levies for 2005, 
compared to $77.21 ± 110.54 (median $35.30) during 2006, $80.42 ± 98.43 (median 
$49.15) in 2007 and $82.76 ± 96.64 (median $52.66) in 2008. CONCLUSIONS: 
Results show that the costs associated with the metabolic syndrome contributes sig-
niﬁ cantly towards the annual expenditure of the South African PBM. Private insurers 
carry most of this burden, although out-of-pocket expenses for patients show an 
increasing trend.
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SUBSTITUTION INFLUENCE FROM MARK DRUGS TO GENERICS IN THE 
ARTERIAL HYPERTENSION THERAPEUTIC COMPLIANCE AND THE 
DYSLIPEMIA IN A POPULATION SETTING
Sicras-Mainar A1, Navarro-Artieda R2
1Directorate of Planning, Badalona Serveis Assistencials, Badalona, Barcelona, Spain; 2Hospital 
Universitari Germans Trias i Pujol, Barcelona, Spain
OBJECTIVES: To determine the therapeutical compliance in subjects with amlodipine 
and simvastatin substitution from mark to generic. Secondary objective: to know the 
professional and patient opinion about its use. METHODS: Patient and methods: 
Before-after design with control group, realized revision of the medical records, in six 
centres of primary care. Participants: Patients ≥ 40 years initiating treatment of mark 
drug (initial period) and after that had a substitution by generic (ﬁ nal period), between 
January 2003 and June 2009. Study groups: arterial hypertension (amlodopine) and 
Dislipemia (simvastatin). Main measures: Co-morbidity, compliance, treatment-time, 
biochemistry objectives and professional-patients opinion (interviews). Continuation: 
Beginning from the generic drug substitution date, each patient was (Minimum) one 
year before with a mark drug and a year after with and generic (minim continuation/
patient: 24 months). RESULTS: A total of 1252 patients. Groups: 49.5% amlodipine; 
50.5% simvastatin. Average age: 72.4 years; women: 48.9%. The ones treated with 
amlodipine (comparing periods); show a better compliance (65.8% vs. 61.3%; p = 
0.037) and arterial pressure control (48.5% vs. 45.8%; p = 0.039) with mark drugs. 
With simvastatin, was 62.8% vs. 58.4%; p = 0.041 (cholesterol control: 66.5% vs. 
60.6%; p = 0.032) respectively. Interviewed doctors: 73.6% prescribe generic and a 
59.2% believe that both have the same efﬁ cacy. Interview patients: a 79.8% (CI: 
74.3–85.3%) accepted substitution; a 55.3% (CI: 48.5–62.1%) received the appropri-
ate information and 61.5% the different products confuse them. a 18.2% declare that 
abandon treatment. CONCLUSIONS: In patients with amlodipine/simvastatin substi-
tution from mark to generics, it was observed less treatment compliance light, with 
minor consecution of control objectives. The realized interviews (professional/patients) 
reafﬁ rm the results.
